{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T05:08:26Z","timestamp":1722316106093},"reference-count":18,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2019]]},"DOI":"10.1620\/tjem.248.37","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T22:03:56Z","timestamp":1558130636000},"page":"37-43","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study"],"prefix":"10.1620","volume":"248","author":[{"given":"Ken","family":"Saijo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Ouchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinari","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Komine","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Shirota","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikashi","family":"Ishioka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","unstructured":"Abdel-Rahman, O., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., Schob, O., Mannhart, M. &amp; Oweira, H. (2017)  Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.  <i>Clin. Oncol. <\/i>(<i>R. Coll. Radiol.<\/i>), 29, 218-230."},{"key":"2","unstructured":"Agrawal, S., Feng, Y., Roy, A., Kollia, G. &amp; Lestini, B. (2016)  Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.  <i>J. Immunother. Cancer<\/i>, 4, 72."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Kong, B., Liniker, E., Guminski, A., Parente, P., Andrews, M.C.,  et al. (2016)  Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.  <i>Br. J. Cancer<\/i>, 114, 1084-1089.","DOI":"10.1038\/bjc.2016.107"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Chang, A.E., Karnell, L.H. &amp; Menck, H.R. (1998)  The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.  <i>Cancer<\/i>, 83, 1664-1678.","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G"},{"key":"5","unstructured":"D\u2019Angelo, S.P., Larkin, J., Sosman, J.A., Lebbe, C., Brady, B., Neyns, B., Schmidt, H., Hassel, J.C., Hodi, F.S., Lorigan, P., Savage, K.J., Miller, W.H. Jr., Mohr, P., Marquez-Rodas, I., Charles, J.,  et al. (2017)  Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis.  <i>J. Clin. Oncol<\/i>., 35, 226-235."},{"key":"6","unstructured":"Del Vecchio, M., Di Guardo, L., Ascierto, P.A., Grimaldi, A.M., Sileni, V.C., Pigozzo, J., Ferraresi, V., Nuzzo, C., Rinaldi, G., Testori, A., Ferrucci, P.F., Marchetti, P., De Galitiis, F., Queirolo, P., Tornari, E.,  et al.  (2014)  Efficacy and safety of ipilimumab 3 mg\/kg in patients with pretreated, metastatic, mucosal melanoma.  <i>Eur. J. Cancer<\/i>, 50, 121-127."},{"key":"7","unstructured":"Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G. &amp; Weber, J.S. (2016)  Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes.  <i>Clin. Cancer Res<\/i>., 22, 886-894."},{"key":"8","doi-asserted-by":"crossref","unstructured":"Fujii, T., Colen, R.R., Bilen, M.A., Hess, K.R., Hajjar, J., Suarez-Almazor, M.E., Alshawa, A., Hong, D.S., Tsimberidou, A., Janku, F., Gong, J., Stephen, B., Subbiah, V., Piha-Paul, S.A., Fu, S.,  et al. (2018)  Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.  <i>Invest. New Drugs<\/i>, 36, 638-646.","DOI":"10.1007\/s10637-017-0534-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Fujisawa, Y., Yoshino, K., Otsuka, A., Funakoshi, T., Uchi, H., Fujimura, T., Matsushita, S., Hata, H., Okuhira, H., Tanaka, R., Nagai, K., Ishida, Y., Nakamura, Y., Furudate, S., Yamamura, K.,  et al. (2018)  Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients.  <i>J. Dermatol. Sci<\/i>., 89, 60-66.","DOI":"10.1016\/j.jdermsci.2017.10.009"},{"key":"10","unstructured":"Hodi, F.S., O\u2019Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., Akerley, W., van den Eertwegh, A.J., Lutzky, J., Lorigan, P., Vaubel, J.M.,  et al. (2010)  Improved survival with ipilimumab in patients with metastatic melanoma.  <i>N. Engl. J. Med<\/i>., 363, 711-723."},{"key":"11","doi-asserted-by":"crossref","unstructured":"Imafuku, K., Yoshino, K., Yamaguchi, K., Tsuboi, S., Ohara, K. &amp; Hata, H. (2017)  Comment on \u2018Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy\u2019.  <i>Br. J. Cancer<\/i>, 116, e14.","DOI":"10.1038\/bjc.2017.58"},{"key":"12","unstructured":"Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P.F., Hill, A., Wagstaff, J., Carlino, M.S., Haanen, J.B.,  et al. (2015)  Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.  <i>N. Engl. J. Med<\/i>., 373, 23-34."},{"key":"13","unstructured":"Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., Linette, G.P., Meyer, N., Giguere, J.K., Agarwala, S.S., Shaheen, M., Ernstoff, M.S., Minor, D., Salama, A.K., Taylor, M.,  et al. (2015)  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.  <i>N. Engl. J. Med<\/i>., 372, 2006-2017."},{"key":"14","doi-asserted-by":"crossref","unstructured":"Postow, M.A., Luke, J.J., Bluth, M.J., Ramaiya, N., Panageas, K.S., Lawrence, D.P., Ibrahim, N., Flaherty, K.T., Sullivan, R.J., Ott, P.A., Callahan, M.K., Harding, J.J., D\u2019Angelo, S.P., Dickson, M.A., Schwartz, G.K.,  et al. (2013)  Ipilimumab for patients with advanced mucosal melanoma.  <i>Oncologist<\/i>, 18, 726-732.","DOI":"10.1634\/theoncologist.2012-0464"},{"key":"15","unstructured":"Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K.J., Hernberg, M.M., Lebbe, C., Charles, J., Mihalcioiu, C.,  et al. (2015)  Nivolumab in previously untreated melanoma without BRAF mutation.  <i>N. Engl. J. Med<\/i>., 372, 320-330."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Weber, J.S., Gibney, G., Sullivan, R.J., Sosman, J.A., Slingluff, C.L. Jr.,  Lawrence, D.P., Logan, T.F., Schuchter, L.M., Nair, S., Fecher, L., Buchbinder, E.I., Berghorn, E., Ruisi, M., Kong, G., Jiang, J.,  et al. (2016)  Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.  <i>Lancet Oncol<\/i>., 17, 943-955.","DOI":"10.1016\/S1470-2045(16)30126-7"},{"key":"17","unstructured":"Wilkins, D.K. &amp; Nathan, P.D. (2009)  Therapeutic opportunities in noncutaneous melanoma.  <i>Ther. Adv. Med. Oncol<\/i>., 1, 29-36."},{"key":"18","doi-asserted-by":"crossref","unstructured":"Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H.E., McHenry, M.B., Waxman, I.M., Achanta, A., Bello, A., Roy, A. &amp; Agrawal, S. (2017)  Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors.  <i>Ann. Oncol<\/i>., 28, 2002-2008.","DOI":"10.1093\/annonc\/mdx235"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/248\/1\/248_37\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T03:40:04Z","timestamp":1558150804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/248\/1\/248_37\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.248.37","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}